ISRCTN17493503 https://doi.org/10.1186/ISRCTN17493503

Deferred registration - Fortrea Clinical Research Unit Code: NMD670-01-0002

Submission date 16/10/2026	**Recruitment status** Not yet recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 02/11/2026	**Overall study status** Deferred	
Last Edited 02/11/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Mr Benjamin Monaghan

Contact details
Fortrea Clinical Research Unit
Drapers Yard
Marshall Street
Holbeck
Leeds
LS11 9EH
United Kingdom
Leeds
United Kingdom
LS11 9EH
+44 1133013512
Benjamin.Monaghan@fortrea.com

Type(s)
Public, Scientific

Contact name
None NMD Pharma A/S Study Contact

Contact details
Palle Juul-Jensens Boulevard 82
Aarhus N
Denmark
DK-8200
-
contact@nmdpharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1014907

Protocol number
NMD670-01-0002

Study information

Scientific Title
A phase 1, open-label, nonrandomized trial to evaluate the absorption, metabolism, excretion (AME) and mass balance of [14C]NMD670 in healthy male participants

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 23/09/2026, London – Central Research Ethics Committee (REC) (2 Redman Place, Stratford, London, E201JQ, United Kingdom; +44 207 104 8197; londoncentral.rec@hra.nhs.uk), ref: 26/LO/07/19

Primary study design
Interventional

Allocation
Non-randomized controlled trial

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose

Phase 1 clinical pharmacology/ADME and mass-balance study.

Study type(s)

Health condition(s) or problem(s) studied
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date. measured using [Metric or method of measurement] at [Timepoint(s)]

Key secondary outcome(s)

Completion date
25/12/2026

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Adult

Lower age limit
35 Years

Upper age limit
55 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
23/11/2026

Date of final enrolment
10/12/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Fortrea Clinical Research Unit
Drapers Yard
Marshall Street
Holbeck
Leeds
LS11 9EH
United Kingdom
Leeds
England
LS11 9EH

Sponsor information

Organisation
NMD Pharma A/S (Denmark)

ROR
https://ror.org/04sb9gc49

Funder(s)

Funder type

Funder Name
NMD Pharma A/S (Denmark)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available